The results were presented at the American College of Phlebology's 24th Annual Congress in Orlando, Florida on November 5, and here today at the 37th Annual VEITH
Symposium on Vascular and Endovascular Issues.
NASDAQ:ELGX), the developer and manufacturer of the Powerlink([R]) System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that the one-year results from its Powerlink XL([R]) prospective, multi-center clinical trial will be presented on November 20, 2008 at the 35th Annual VEITH Symposium[TM] being held in New York City.
Additional presentations at the VEITH Symposium featuring the Powerlink System are as follows:
Nasdaq:ELGX) today reported that favorable Powerlink([R]) System clinical data was featured in two presentations on Saturday, November 17 at the 34th Annual VEITH Symposium in New York City.
These presentations underscore the fact that the Powerlink System provides important technology that can meet the expanding role of EVAR and we are exceptionally pleased that this message was delivered at the prestigious VEITH Symposium.
Professor of Surgery at UCLA School of Medicine and Chief of Vascular Surgery at Harbor-UCLA Medical Center, presented the data at the VEITH
symposium(TM) in New York on Saturday, November 19.